> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Recurrent Herpes Labialis Drug Development
- URL: https://www.fdaweb.com/guide-on-recurrent-herpes-labialis-drug-development-2/
- Published: 2017-11-08T12:00:00.000Z
- Updated: 2026-09-14T23:00:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140083

*Federal Register* notice: FDA has made available a guidance on “Recurrent Herpes Labialis (RHL): Developing Drugs for Treatment and Prevention.” The document is intended to assist sponsors in all development phases of development and it also addresses prevention of RHL. It outlines the types of nonclinical studies and clinical trials recommended to support approval of such antiviral drug products. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-08/pdf/2017-24308.pdf?ref=fdaweb.com).